Apr 4, 2009

European Rett Syndrome Congress, June 5-7, Milan, Italy

1st European Congress on Rett Syndrome - Università degli Studi di Milano, June 5-7, 2009

Rett Syndrome is a rare disease which springs from a genetic mutation of a specific gene, the MECP2, and provokes severe problems to the "girls with beautiful eyes", including neurological disfunctions in movement and development of the brain, cardiac problems, gastric disfunctions and many others.

We need your help to substain AIR (Associazione Italiana Sindrome di Rett) and RSE (Rett Syndrome Europe) and divulgate the results of recent researches on the disease.
Please help us make Rett Syndrome a studied and well-known disease, registering to the congress and bringing your contribution through submittance of an abstract through the web site www.aimgroup.it/29009/airett.

AIR
RSE
The Organizing Secretariat

Click here to download the files.

Rett gene plays crucial role in glia

Study says Rett gene's role in glia, not neurons, crucial to syndrome

MECP2, the gene that causes the autism-related Rett syndrome, is expressed not just in neurons but in glia — cells that support neurons and help process information — in the brain, according to a study published online in the March issue of Nature Neuroscience 1.

What’s more, it’s MeCP2’s loss from these glia, and not from neurons, that appears to be important in causing the disorder. Glia make up roughly 90 percent of cells in the nervous system, and are thought to be crucial for the survival and maturation of neurons.

Rett syndrome is a rare neuro-developmental disorder that affects girls within the first 18 months of life. Beginning with delayed growth and speech, the disorder progresses and, as a result of severe impairments in motor function, often leaves girls wheelchair-bound by their early 20s.

A decade ago, Huda Zoghbi and her team first linked mutations in MeCP2 to the disorder2. Mutations in the same gene, which has been found to activate and repress thousands of other genes, are also found in people with learning disabilities, mental retardation and autism.

Several studies of Rett syndrome had reported MeCP2’s presence in neurons, but not in glia3. But a few years ago, some researchers began looking closer at the gene’s expression in glia because it is present in many other non-neuronal cell types — such as fibroblasts and muscle cells — outside the brain, says Nurit Ballas.

Ballas, who conducted the work as a research associate in the lab of Gail Mandel, is now associate professor of chemistry and cell biology at Stony Brook University in New York.

“I thought, ‘Why would I not see [MeCP2] in glia?’” Ballas recalls. She decided to use a sensitive antibody and a new way of staining for the protein that could enhance the signal.

Diverse locations:
She and her colleagues found that MeCP2 is present in all types of healthy mouse glia, including astrocytes — star-shaped cells that help regulate a neuron’s chemical environment — and oligodendrocytes, which form a protective sheath over neurons. In contrast, the protein is not detectable in the glia of mouse models of Rett syndrome.

Neurons cultured on a bed of astrocytes taken from Rett mice also have fewer and shorter dendrites — the long fibers of neurons that receive signals — compared with neurons cultured on healthy astrocytes.

Conversely, adding healthy astrocytes to neurons that lack MeCP2 restores the growth of dendrites in those neurons.

“To me the biggest surprise came from the fact that an astrocyte that doesn’t have this protein is compromised in its capacity to support neurons,” says Zoghbi, a Howard Hughes Medical Institute Investigator at the Baylor College of Medicine in Houston.

Even the astrocyte-conditioned medium — a nutrient broth secreted by astrocytes that can normally support neuron growth in culture — from the Rett mice stunts proper development of neurons.

The researchers are trying to selectively eliminate MeCP2 from mouse astrocytes and other glia in order to determine the relative roles of these cells in triggering Rett syndrome.

“We also want to know what the factors are in the media that astrocytes are secreting, and whether that plays a role in Rett,” Mandel says.

Because MeCP2 normally controls the expression of many genes, the lack of a functional MeCP2 in these astrocytes could stunt the neurons’ growth by somehow altering the chemical milieu in a neuron’s environment, the authors note.

“If it is true that the astrocytes are secreting a toxic inhibitory factor,” Mandel adds, “then that’s a point of potential pharmaceutical intervention.”


Zie http://sfari.org/news/study-says-rett-gene-s-role-in-glia-not-neurons-crucial-to-syndrome

Feb 11, 2009

A possible treatment for Rett syndrome

Study suggests molecule can reverse some symptoms
CAMBRIDGE, Mass.— A molecule that promotes brain development could serve as a possible treatment for Rett syndrome, the most common form of autism in girls, according to researchers at MIT's Picower Institute for Learning and Memory and the Whitehead Institute for Biomedical Research.
The researchers found that injecting the molecule into mice that have an equivalent of Rett syndrome helped the animals' faulty brain cells develop normally and reversed some of the disorder's symptoms.
The work, reported in the Feb. 10 online edition of the Proceedings of the National Academy of Sciences (PNAS), is expected to lead to new human clinical trials for a derivative of growth factor-1 (IGF-1), currently used to treat growth disorders and control blood glucose. The MIT study indicates that IGF-1 could potentially lessen the severity of symptoms of Rett syndrome.
"We demonstrate that a major underlying mechanism behind Rett syndrome in mice is that synapses in the brain remain immature and show persistent, abnormal plasticity into adulthood," said Daniela Tropea, a postdoctoral fellow at the Picower Institute and lead author of the study. "We also propose that a therapeutic based on this mechanism would be directly applicable to humans."
Injecting mice with a peptide fragment of IGF-1, used by the brain for neuronal and synaptic development, reverses a large number of symptoms of mice genetically engineered to display Rett syndrome-like symptoms.
"IGF-1 is critical for brain development. It activates molecules within neurons that make synapses mature," said study co-author Mriganka Sur, the Newton Professor of Neuroscience at the Picower Institute and head of the MIT Department of Brain and Cognitive Sciences. "This is a mechanism-based therapeutic for Rett syndrome. It is possible that this or similar therapeutics would apply to other forms of autism, which also have as their basis a persistent immaturity of synapses."
HELPING NERVE CELLS MATURE
Rett syndrome, an inherited neurological disorder, causes loss of speech, reduced head size, breathing and heart abnormalities and autism-like symptoms in one out of 10,000 girls.
In 85 percent of girls with Rett syndrome, the culprit is a faulty gene coding for methyl CpG-binding protein 2, (MeCP2), critical for nerve cell maturation. A deficit in MeCP2 stops neurons from growing spines, the branch-like projections needed for cell-to-cell communication.
Recent genetic studies have shown that increasing MeCP2 expression in mice led neurons to grow new spines, indicating that the disease could be reversible. Increased IGF-1 seems to make up for the lack of MeCP2.
Daily injections of the insulin-like growth factor IGF-1 extended the life spans of infant Rett syndrome mice, improved their motor function and breathing patterns and reduced irregularities in their heart rates. In addition, their brains had more nerve-cell spines.
IGF-1 affects almost every cell in the human body, especially in muscle, cartilage, bone, liver, kidney, nerves, skin and lungs. In addition to its insulin-like effects, IGF-1 also regulates cell growth and development in nerve cells.
"This is the first realistic way for a drug-like molecule injected into the bloodstream to relieve Rett syndrome symptoms," said Whitehead member Rudolf Jaenisch, whose lab participated in the research.

ScienceDaily

Rett Syndrome Blogs

Medical news